Skip to main content
. Author manuscript; available in PMC: 2012 Nov 21.
Published in final edited form as: Vaccine. 2011 Oct 12;29(50):9361–9367. doi: 10.1016/j.vaccine.2011.09.133

Figure 4. Vaccination with Ad-HER2-C1C2 elicits superior anti-tumor responses against HER2+ cells in human HER2 transgenic mice.

Figure 4

BALB/c HER2+ transgenic mice were implanted with 2×104 4T1-HER2+ cells at day zero and vaccinated with 2.6×1010 vp of the indicated Ad vectors (A and B) where indicated by arrows (4, 11, and 18 dpi). For all conditions, N=6-8 and error bars denote SE. In all samples, * and ** denotes conditions that showed p<0.05 and p<0.01 respectively, compared to Ad-LacZ (A) or PBS (B) controls. Additionally, # and ## denote conditions that showed p<0.05 and p<0.01 respectively to Ad-HER2/C1C2ECD injected animals (A).